- Inovio Pharmaceuticals (NYSEMKT:INO) is up 5% premarket on light volume on the heels of its announcement of positive preliminary results from a Phase 1 clinical trial assessing the safety, tolerability and immunogenicity of hepatitis B virus (HBV) DNA immunotherapy candidate INO-1800, alone or in combination with INO-9112, in 90 adults with chronic HBV infection.
- The open-label, dose escalation study met the primary endpoints of safety and tolerability. On the efficacy front, patients treated with INO-1800 experienced a generation of T cells that recognized key components of the hepatitis B virus and reacted by generating antiviral proteins that play a key role in clearing HBV from the liver.
- Additional data will be submitted for presentation at future medical conferences and for publication.
- The company says more than 240M people are living with chronic HBV infection, adding that currently available treatments may only slow the progression of the disease.
- It is seeking a collaboration partner to advance INO-1800.
- Now read: Regeneron Looks To Capitalize On New Praluent Data
Original article